Search

 
 

Associate-Professor Candidate of Medical Sciences Olga Ponomaryova have attended on November, 2-5, 2019, the yearly event – the European Oncogynecological Congress, which was held in Athens (Greece) casually under supervision of ESGO – European Society of Oncogynecologists. The Congress have had prominent trend in multidisciplinary agenda and ideology. Leading scientist from all over the world, and from Europe especially, have devoted their communications and lectures to modern algorithms of diagnosis and treatment of oncogynecological patients.

Significant changes, taking place in the guidelines scenarios through last 15 years, have stressed the importance for universal introduction of individualized complex (multimodal) planning of perioperative treatment in this group of patients. Nowadays the global efforts in oncogynecology are directed on continuous scientific-practical movement towards the treatment results optimization, including preserving of quality of life in the patients and  convalescents. In this tendency, taking place in EU and Ukraine as well, the progressive elements of implementation of globally spread programs, concerning harmonic development of oncogynecological branch of medicine under the mottos of evidence-based science, intelligence and adequacy.

Very interesting information was demonstrated, concerning a new approaches and procedures in miniinvasive surgeries, and in a robotic-assisted one especially, etc. Thus, the approaches, guaranteeing the quality of life preservation in very invasive oncological treatment, taking place, is succeeded due to the miniinvasive surgical procedures implementation.

Precise oncological staging is provided now, using laparoscopic possibilities in part, promoting an adequate planning of the treatment strategy in the aspects of  content and volume of medicinal, radiation and surgical treatment.

During last year’s positive and unequivocal data were obtained simultaneously, concerning several preliminary and final results on hyperthermic abdominal chemoperfusion therapy. The scientists proceed now with investigations of causes of the lower efficacy of this method in peritoneal canceromatosis in disseminated ovarian cancer. Today the most perspective group of preparations – іnhibitors of PARP – is less effective in canceromatosis, then secondary optimal surgical cytoreduction.

Separate session on the Congress was devoted to the issues, concerning the improvement of the quality of life medical aspects in oncogynecological patients, especially while treating serious side effects and complications of, accordingly, the medicinal, radiation and surgical modes.

Special communications were made on essential aspects of oncological supportive care, including nutritive issues. Peculiarities of anesthesiological support were discussed with special interest during last decades globally, so this time the team from Great Britain have presented very sophisticated presentation on the problem.

Several sections of the Congress have worked on the issues of oncological special treatment while pregnancy and securing of reproductive possibilities in women-patients after antitumoral therapy have succeeded. This paramountly significant multidisciplinary task in therapeutic oncogynecological management was discussed thoroughly. Most modern decisions of this problem are enlightened in the Thematic Improvement Course, which is provided in the Department of Oncology of the Shupyk National Medical Academy of Postgraduate Education (City of Kyiv, Ukraine) under supervision of Doctor of Medical Sciences Natalia Tsip On the Congress the actuality and need for scientific and practical international cooperation were stressed. Besides ESGO – European Society of Oncogynecologists – there was created and proceeds great activity the ENGOT - European Network of Gynaecological Oncological Trial Groups. Іntegration into this highly professional environment would promote further successful progress of Ukrainian research community in taking part in multicenter RCTs with inevitable profound gains for our oncogynecological patients, suffering various forms and stages of genital cancers.